Allarity Therapeutics (Allarity Therapeutics) Cash-to-Debt : 0.12 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Allarity Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.12.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Allarity Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Allarity Therapeutics's Cash-to-Debt or its related term are showing as below:

ALLR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 1.2 Max: 41.99
Current: 0.12

During the past 5 years, Allarity Therapeutics's highest Cash to Debt Ratio was 41.99. The lowest was 0.08. And the median was 1.20.

ALLR's Cash-to-Debt is ranked worse than
93.74% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs ALLR: 0.12

Allarity Therapeutics Cash-to-Debt Historical Data

The historical data trend for Allarity Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Allarity Therapeutics Cash-to-Debt Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.58

0.11

18.33

0.54

0.13

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											0.08	0.28	1.20	0.13	0.12

Competitive Comparison of Allarity Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Allarity Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Cash-to-Debt falls into.

Allarity Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Allarity Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.166	/	(1.3	+	0)
	=	0.13

Allarity Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.312	/	(2.69	+	0)
	=	0.12

Allarity Therapeutics (NAS:ALLR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Allarity Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics (Allarity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 School Street, 2nd Floor, Boston, MA, USA

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Executives

Laura Benjamin	director	168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano	director	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown	officer: Chief Financial Officer	C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi	director, officer: Chief Executive Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen	officer: Chief Scientific Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen	officer: Chief Financial Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore	director	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen	officer: SVP, Information Technology	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem	officer: SVP, Chief Business Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh	officer: Chief Medical Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps	10 percent owner	VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass	10 percent owner	JERNBAEK ALLE 5, HELSINGE G7 DK-3200